BMS/Natco Sprycel spat could reignite patent linkage debate in India
This article was originally published in Scrip
Executive Summary
India is set to hear yet another significant patent-related case next month, this time concerning Bristol-Myers Squibb's anticancer, Sprycel (dasatinib), though Natco's "at-risk" launch of a cut-price generic version may put the spotlight back on the controversial issue of linking patents and regulatory approvals in the country.